Artificial Oocyte Activation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-22

Study Completion Date

2024-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of Artificial Oocyte Activation Technique (AOA) in ART

NCT04519918

Fertilization

UNKNOWN NA

Successful Pregnancy and Delivery After AOA

NCT01595815

Infertility

COMPLETED NA

Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score

NCT07020546

Infertility Poor Ovarian Reserve Embryo Growth Disorder +1 more

RECRUITING NA

How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome

NCT00878124

Poor Ovarian Response

TERMINATED NA

Improving the Reproductive Outcome of Poor Quality Ova by Injection of Autologous Somatic Mitochondria

NCT01631578

Low Ovarian Reserve Poor Quality Oocytes

WITHDRAWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Ovarian Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)

women having had a second IVF cycle with AOA

Intervention Type OTHER

The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.

In-vitro fertilization (IVF) cycle without artificial oocyte activation (AOA)

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

women having had a second IVF cycle with AOA

The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with poor or no blastocyst development in their primary cycle
* Group 1 - second cycle using AOA following the poor blastocyst development cycle
* Group 2 - second cycle without AOA following the poor development cycle